超声引导下经皮激光消融治疗单灶T1N0M0甲状腺微小乳头状癌的初步结果
回顾性研究纳入30例经细针穿刺活检确诊的单灶T1N0M0甲状腺微小乳头状癌患者,行超声引导下经皮激光消融,即刻及7天后用超声造影评估消融范围并记录并发症。29例在局部麻醉下单次消融成功,1例即刻超声造影发现消融不完全而再次消融,随访未见肿瘤再生长、局部复发或远处转移。作者认为短期随访内超声引导下经皮激光消融对不适合手术的特定单灶T1N0M0甲状腺微小乳头状癌患者似乎有效且安全。
要点
- 超声引导下经皮激光消融可作为不适合手术的单灶T1N0M0甲状腺微小乳头状癌的候选治疗。
- 术后即刻超声造影可发现消融不完全,本组1例因此接受第二次消融。
- 末次随访时33.3%消融区消失、66.67%残留瘢痕样病灶,未见肿瘤再生长、局部复发或远处转移。
核心结论
- 短期随访内,超声引导下经皮激光消融对不适合手术的特定单灶T1N0M0甲状腺微小乳头状癌患者似乎有效且安全。
研究设计与样本
- 回顾性研究,纳入30例经细针穿刺活检确诊的单灶T1N0M0甲状腺微小乳头状癌患者,行超声引导下经皮激光消融,用超声造影评估消融范围。
关键影像表现/征象
- 消融后即刻超声造影发现1例消融不完全,随即行第二次消融。
- 末次随访时10个(33.3%)消融区消失,20个(66.67%)消融区残留为瘢痕样病灶。
- 随访期间未检出治疗肿瘤再生长、局部复发或远处转移。
诊断标准与关键数值
- 入组对象为经细针穿刺活检确诊的单灶T1N0M0甲状腺微小乳头状癌患者。
- 消融范围于消融后即刻及消融后7天用超声造影评估。
- 消融区大小、体积及甲状腺激素于1、3、6、12个月及此后每半年复查评估。
局限性
- 原文标题写明为初步结果(Preliminary results)。
- 原文结论限定为短期随访期内,超声引导下经皮激光消融对特定不适合手术患者似乎有效且安全。
- 原文结论限定适用人群为不适合手术的特定(selected)患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the efficacy and safety of percutaneous laser ablation (PLA) for unifocal T1N0M0 papillary thyroid microcarcinoma(PTMC).
METHODS: A retrospective study was conducted in 30 patients with single PTMC which was diagnosed by fine-needle aspiration biopsy (FNAB). PLA was performed for proper time to achieve adequate ablation zones. The extent of ablation was assessed by contrast-enhanced ultrasound (CEUS) immediately and 7 days after PLA. Complications were recorded. The size and volume of the ablation area and thyroid hormones were measured, and clinical evaluations were performed at 1, 3, 6 and12 months, and every half year thereafter.
RESULTS: The procedure was well tolerated without serious complications. Of the 30 patients, 29 were treated successfully under local anaesthesia in a single session. Only one incomplete ablation was detected by immediate CEUS after PLA, and a second ablation was performed. At the last follow-up, ten (33.3 %) ablation zones had disappeared, and 20 (66.67 %) ablation zones remained as scar-like lesions. No regrowth of treated tumours, local recurrence or distant metastases were detected.
CONCLUSIONS: During the short-term follow-up period, ultrasound-guided PLA appears to be effective and safe for treating solitary T1N0M0 PTMC in selected patients who are ineligible for surgery.
KEY POINTS: • Ultrasound is a useful tool in percutaneous laser ablation (PLA). • PLA is safe for treating papillary thyroid microcarcinoma. • PLA is effective for single papillary thyroid microcarcinoma.
引用
- Zhou W, Jiang S, Zhan W, et al. Ultrasound-guided percutaneous laser ablation of unifocal T1N0M0 papillary thyroid microcarcinoma: Preliminary results. Eur Radiol. 2016. PMID: 27853812. doi:10.1007/s00330-016-4610-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。